

Epclusa® (sofosbuvir/velpatasvir) – Expanded indication, New strength

- On March 19, 2020, the <u>FDA announced</u> the approval of <u>Gilead's Epclusa (sofosbuvir/velpatasvir)</u>, for the
 treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic
 hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection:
 - Without cirrhosis or with compensated cirrhosis
 - With decompensated cirrhosis for use in combination with ribavirin.
- Epclusa was previously approved for this indication in adults only.
- In addition to the expanded indication, the FDA also approved a 200 mg/50 mg tablet strength of Epclusa. It was previously only available as a 400 mg/100 mg tablet.
- The approval of Epclusa for the expanded indication was based on an open-label study in 173 genotype 1, 2, 3, 4, or 6 HCV treatment-naïve or treatment-experienced pediatric patients 6 years of age and older without cirrhosis or with compensated cirrhosis. The primary endpoint was the cure rate, as measured by the sustained virologic response (SVR) 12 weeks after the cessation of treatment.
 - In patients 12 years to < 18 years of age, the SVR rate was 93% (71/76) in patients with genotype 1 HCV infection and 100% in patients with genotype 2 (6/6), genotype 3 (12/12), genotype 4 (2/2), and genotype 6 (6/6) HCV infection.</p>
 - In patients 6 years to < 12 years of age, the SVR rate was 93% (50/54) in patients with genotype 1 HCV infection, 91% (10/11) in patients with genotype 3 HCV infection, and 100% in patients with genotype 2 (2/2), and genotype 4 (4/4) HCV infection.
- Epclusa carries a boxed warning for risk of hepatitis B virus (HBV) reactivation in patients coinfected with HCV and HBV.
- The recommended dose of Epclusa for the treatment of HCV in pediatric patients 6 years of age and older or weighing at least 17 kg is based on weight and liver function.

Body weight (kg)	Dosing of Epclusa	Epclusa daily dose
≥ 30	one 400 mg/100 mg tablet once daily or two 200 mg/50 mg tablets once daily	400 mg/100 mg per day
17 to < 30	one 200 mg/50 mg tablet once daily	200 mg/50 mg per day

- In treatment-naïve and treatment-experienced patients, without cirrhosis and with compensated cirrhosis (Child-Pugh A), the treatment regimen is Epclusa for 12 weeks.
- In treatment-naïve and treatment-experienced patients, with decompensated cirrhosis (Child-Pugh B or C), the treatment regimen is Epclusa plus ribavirin for 12 weeks.
- Refer to the Epclusa drug label for complete dosing recommendations, including dosing of ribavirin and dosing in adults.
- Gilead's launch plans for the 200 mg/50 mg tablet strength are pending.



optumrx.com

OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.